CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 28 enrolled
Drug / intervention
Adapalene/benzoyl peroxide gel, 0.1%/2.5% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02249104
NCT02249104Phase 4Completed

Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris

Galderma R&D·interventional·Posted Sep 25, 2014·Updated Aug 23, 2022

In Brief

A Phase 4 clinical trial evaluating Adapalene/benzoyl peroxide gel, 0.1%/2.5% and Cetaphil Acne Regimen for Acne Vulgaris. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The goal of this study is to evaluate a complete topical acne regimen consisting of a prescription acne medication (Epiduo® Gel) and an acne-specific cleanser (Cetaphil® DermaControl™ Foam Wash) and moisturizer with sunscreen (Cetaphil® DermaControl™ Moisturizer SPF 30) for safety, efficacy and patient satisfaction in student athletes with acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 25, 2014
Enrollment StartAug 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.8 years ago

Interventions

Adapalene/benzoyl peroxide gel, 0.1%/2.5%drug

Topical AV therapy

Cetaphil Acne Regimenother

Cleanse, Moisturize, and Protect